Registration - Consultant

Subject Matters

• Economic Development
• Government Procurement
• Health
• Internal Trade
• International Trade
• Justice and Law Enforcement
• Privacy and Access to Information
• Research and Development

Subject Matter Details

Legislative Proposal, Bill or Resolution

• Participation in consultations regarding the Digital Charter and the federal government's plans to overhaul Canada's privacy regime, to enable the use of anonymized health data for new medication research and development.
• Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation.

Policies or Program

• Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.
• Engage the government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians.
• Engagement with government officials on disruptions to business, health & safety requirements, and opportunities to help with the COVID-19 pandemic.
• Ensure the National Advisory Committee on Immunization has sufficient resources to undertake timely reviews of new vaccines that are made available to the Canadian marketplace.
• Harmonizing rules for the sampling of natural health products under the proposed Canada-United States-Mexico trade agreement.
• Input on the work of the Advisory Committee on the Implementation of National Pharmacare, specifically as it relates to access to medicines.
• Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors.
• Sharing information with government and Members of Parliament on different models for national pharmacare, specifically as it relates to access to medicines.
• The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements.

Regulation

• Allow for the regulation of products containing cannabidiol (CBD) as natural health products.
• Engaging Health Canada on the Self-Care Products Initiative as it pertains to plain language labelling and a risk-based approach to regulatory oversight for non prescription drugs.
• Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada.

Communication Techniques

• Written communication
• Oral communication
• Grass-roots communication

Government Institutions

• Canadian Heritage (PCH)
• Employment and Social Development Canada (ESDC)
• Health Canada (HC)
• House of Commons
• Innovation, Science and Economic Development Canada (ISED)
• Justice Canada (JC)
• Patented Medicine Prices Review Board (PMPRB)
• Prime Minister's Office (PMO)
• Senate of Canada
• Treasury Board Of Canada Secretariat (TBS)

Address:
7333 Mississauga Road North
Mississauga, ON  L5N 6L4
Canada

Telephone number: 905-819-3000
Web address: http://ca.gsk.com/

Client representative

Ryan Lock, Lead - Federal Affairs and Public Policy

Parent Company Information